Industry Pipeline - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Pipeline
Interphex Showcase 2010.

Pharmaceutical Technology
Volume 34, Issue 4, pp. 128-135

PACKAGING EQUIPMENT & SUPPLIES



Transfer packaging for prefillable syringes
BD TSCF packaging ensures the secure transfer of sterile prefillable syringe components into the pharmaceutical filling environment. The packaging is compatible with IDC Biosafe doors for aseptic filling machines within isolator or barrier systems. This packaging is part of the BD SCF global offer, which features expertise in sterile processing of preservative-free drugs; secure, reliable, easy-to-use systems; sterile, ready-to-fill; and drug master file and technical dossier. BD Medical–Pharmaceutical Systems, Franklin Lakes, NJ http://www.bdpharma.com/ tel. 800.225.3310



Packaging solution
The NextBottle package from Catalent and One World Design and Manufacturing Group is designed to improve patient compliance. The product's dial mechanism dispenses one pill at a time and automatically reminds patients of the last day that a pill was taken. Catalent Pharma Solutions, Somerset, NJ http://www.catalent.com/ tel. 866.720.3148



Packaging technologies
Confab complements its modified-release expertise with dry-coated, core-centered tablets. The company is expanding its liquid unit-dose packaging, and new technologies allow it to package small containers with syringes or droppers into a carton. The company also has launched an updated, interactive website. Confab, Saint-Hubert, Canada http://www.confab.com/ tel. 450.443.6666


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here